Brief: Nurix Therapeutics Presents Positive Clinical Results From Its Novel BTK Degrader (Nx-2127)
12/12/2022 22:41
Dec 12 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS PRESENTS POSITIVE CLINICAL RESULTS FROM
ITS
NOVEL BTK DEGRADER (NX-2127) AT THE 64TH AMERICAN SOCIETY OF
HEMATOLOGY (ASH) ANNUAL MEETING
Source text for Eikon: ID:nGNX2nBrbL
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis